1
EXHIBIT 10.46
FUNDED RESEARCH & DEVELOPMENT AND LICENSE AGREEMENT
THIS AGREEMENT is made by and between i-STAT Corporation ("i-STAT"), a
Delaware corporation having its principal place of business at ▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇
▇▇▇▇, ▇▇▇▇▇▇▇▇▇, ▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇ and ▇▇▇▇▇▇ Laboratories ("Abbott"), an
Illinois corporation having its principal place of business at ▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇
▇▇▇▇, ▇▇▇▇▇▇ ▇▇▇▇, ▇▇▇▇▇▇▇▇ ▇▇▇▇▇-▇▇▇▇.
WITNESSETH:
WHEREAS, Abbott has experience in the research, development,
manufacture and marketing of diagnostic tests;
WHEREAS, i-STAT has experience in the research, development,
manufacture and marketing of medical diagnostic products for point-of-care
analysis;
WHEREAS, i-STAT and Abbott have conducted discussions regarding
collaboratively developing diagnostic tests for commercialization that utilize
and adapt i-STAT Know-How and Technology (as hereinafter defined) and Abbott
Know-How and Technology (as hereinafter defined);
WHEREAS, Abbott desires to provide i-STAT with funding for such
research and development work,
WHEREAS, i-STAT agrees to perform such research and development work;
WHEREAS, i-STAT has entered into a Distribution Agreement with FUSO
Pharmaceutical Industries, Ltd. and JCR Pharmaceutical Co. Ltd. (together
"FUSO") dated August 23, 1988 ("FUSO Agreement") for the distribution of certain
of such i-STAT products in
2
2
Japan, South Korea and Taiwan and, on the same date, has entered into a
Development Agreement with FUSO (the "FUSO Development Agreement") and a
Manufacturing License Agreement with FUSO (the "FUSO License Agreement");
WHEREAS, i-STAT has entered into a Distribution Agreement with
Hewlett-Packard Company ("HP") dated July 28, 1995 ("HP Agreement") for the
distribution of certain of such i-STAT products in Europe, the Middle East and
Africa, and on the same date, entered into a License Agreement with HP ("HP
License Agreement") for the license rights to certain i-STAT intellectual
property in Europe, the Middle East and Africa;
WHEREAS, concurrent with this Agreement, i-STAT and Abbott are
executing stock purchase and related agreements by which Abbott shall acquire a
minority ownership interest in i-STAT ("Stock Purchase Agreements");
WHEREAS, concurrent with this Agreement, i-STAT and Abbott are
executing a distribution agreement by which Abbott shall obtain exclusive or
co-exclusive rights to distribute i-STAT Products (as hereinafter defined) and
exclusive rights to distribute Program Products (as hereinafter defined) in the
Field (as hereinafter defined) ("Marketing and Distribution Agreement" and,
together with this Agreement and the Stock Purchase Agreements, the "Alliance
Agreements").
NOW, THEREFORE, in consideration of the mutual covenants and agreements
contained herein, and subject to the terms and conditions set forth below,
i-STAT and Abbott hereby agree as follows:
3
3
ARTICLE 1. DEFINITIONS
The following words and phrases, when used herein with initial capital
letters, shall have the meanings set forth or referenced below:
1.1 "Abbott Know-How and Technology" shall mean ▇▇▇▇▇▇'▇ and its
Affiliates' (as hereinafter defined) proprietary rare reagents, immunoassay
system technology, calibrators and controls and accompanying detection
technology, including, but not limited to, manufacturing or production
techniques, formulations, methods, products and processes, and any and all
patents, patent applications, Trademarks (as hereinafter defined), trade names,
service marks, copyrights, know-how, Trade Secret (as hereinafter defined) or
other proprietary rights of Abbott and its Affiliates relating thereto, that are
owned or licensed by Abbott or its Affiliates prior to the Closing Date (as
hereinafter defined) or are extensions to ▇▇▇▇▇▇'▇ proprietary rare reagents,
immunoassay system technology, calibrators and controls and accompanying
detection technology, developed after the Closing Date in programs funded
outside the R&D Program (as hereinafter defined).
1.2 "Actual Cost" shall mean ***
*** CONFIDENTIAL TREATMENT REQUESTED.
4
4
1.3 "Affiliate" shall mean, with respect to each Party (as hereinafter
defined), any legal entity that is, directly or indirectly, controlling,
controlled by or under common control with such Party. For purposes of this
definition, a Party shall be deemed to control another entity if it owns or
controls, directly or indirectly, more than fifty percent (50%) of the voting
equity of the other entity (or other comparable ownership interest for an entity
other than a corporation).
1.4 "Analyte" shall mean an individual compound, protein or fragment
thereof, or substance which is the target of quantitative or qualitative
measurement.
1.5 "Analyzer" shall mean a device that processes Cartridges (as
hereinafter defined) and is capable of detecting at least one (1) Analyte for
use in the Field (as hereinafter defined), including analyzers integrated into
in vitro diagnostic devices, but excluding analyzers which are not integrated
into in vitro diagnostic devices, which devices are designed primarily for the
delivery of patient care (e.g., the monitors currently being marketed and
distributed by HP pursuant to a license from i-STAT).
1.6 "Ancillary Products" shall mean any hardware (not including
Cartridges) and/or software that is not part of an Analyzer, but is essential to
the use of an Analyzer (e.g., a simulator device used for testing Analyzers by
simulating certain of the electrical characteristics of a Cartridge or by some
other testing means) and which is identified on Schedule 1.6 as may be amended
from time to time.
1.7 "AUP" shall mean the average unit selling price.
5
5
1.8 "Business Day" shall mean any day other than a day which is a
Saturday or Sunday or other day on which commercial banks in New York, New York
are authorized or required to remain closed.
1.9 "Calendar Quarter" shall mean a period of three (3) consecutive
calendar months commencing on January 1, April 1, July 1 or October 1 of any
Contract Year (as hereinafter defined).
1.10 "Cartridge" shall mean the disposable component of a Program
Product that contains the i-STAT Sensors (as hereinafter defined) and fluid
handling channels and operate on the Analyzer or any other analyzer or
integrated device sold by a Third Party (as hereinafter defined) under an
agreement with i-STAT.
1.11 "Change of Control" shall mean: (a) the consolidation or merger of
i-STAT or any Affiliate of i-STAT with or into any Third Party (as hereinafter
defined) wherein the shareholders of i-STAT immediately prior to such
transaction shall cease to be the holders of at least fifty percent (50%) of the
outstanding securities of the surviving corporation in such transaction; (b) the
assignment, sale, transfer, lease or other disposition of all or substantially
all of the assets of i-STAT; or (c) the acquisition by any Third Party or group
of Third Parties acting in concert, of beneficial ownership (within the meaning
of Rule 13d-3 of the Securities and Exchange Commission ("SEC") under the
Securities and Exchange Act of 1934) of more than fifty percent (50%) of the
outstanding shares of voting stock of i-STAT.
1.12 "Closing" shall mean the closing of the transaction provided for
in this Agreement, as more fully described in Article 14.
1.13 "Closing Date" shall mean the date on which the Closing occurs.
6
6
1.14 "Co-exclusive FUSO Territory" shall mean the territory into which
FUSO currently has the right to distribute certain i-STAT Products on a
non-exclusive basis pursuant to the FUSO Agreement, which territory shall be
reduced from time to time pursuant to Section 4.4. As of the Signing Date (as
hereinafter defined), the Co-exclusive FUSO Territory consists of Japan, South
Korea and Taiwan.
1.15 "Commercialize" or "Commercialization" shall mean to promote,
market, sell and/or distribute.
1.16 "Confidential Information" shall mean any and all technical data,
information, materials and other know-how including Trade Secrets presently
owned by or developed by, on behalf of, or derived either directly or indirectly
from Program Technology (as hereinafter defined) of either Party and/or its
Affiliates during the Term (as hereinafter defined) which relates to an i-STAT
Product or a Program Product, its development, manufacture, promotion,
marketing, distribution, sale or use, and any and all financial data and
information relating to the business of either of the Parties and/or of their
Affiliates, which a Party and/or its Affiliates discloses to the other Party
and/or its Affiliates in writing and identifies as being confidential, or if
disclosed orally, visually or through some other media, is identified as
confidential at the time of disclosure and is summarized in writing within
thirty (30) days of such disclosure and identified as confidential, except any
portion thereof which:
(a) is known to the receiving Party and/or its Affiliates at the
time of disclosure, as evidenced by its written records;
7
7
(b) is disclosed to the receiving Party and/or its Affiliates by a
Third Party having a right to make such disclosure;
(c) becomes patented, published, or otherwise part of the public
domain through no fault of the receiving Party and/or its
Affiliates; or
(d) is independently developed by or for the receiving Party
and/or its Affiliates without use of Confidential Information
disclosed hereunder, as evidenced by its written records.
1.17 "Contract Year" shall mean a calendar year during the Term
beginning on January 1, except that the first Contract Year may begin on the
Starting Date, and shall end on December 31, 1999.
1.18 "Date of First Market Launch" shall mean the date on which Abbott
or its Affiliates first transfer title to and sell Program Product (other than a
Program Product used for clinical studies) to a Third Party in the Territory (as
hereinafter defined) after receipt of regulatory approval (if required in such
country of first market launch).
1.19 "Distributor Territories" shall mean those countries identified on
Schedule 1.19, as may be amended from time to time in accordance with the
provisions of Section 4.4.
1.20 "FDA" shall mean the United States Food and Drug Administration or
any successor agency thereto.
1.21 "Field" shall mean the professionally attended human healthcare
delivery market, including, without limitation, hospitals, physician office
laboratories, alternate site facilities, surgi-centers, emergicare, ambulances
and home care. Subject to ▇▇▇▇▇▇'▇ right of first negotiation as set forth in
Section 2.5 of the Marketing and Distribution Agreement, Field shall not include
the consumer self-testing market.
8
8
1.22 "510K Filing" shall mean a pre-market notification submission
filed with the FDA requesting clearance to distribute commercially a medical
device for human use in the United States (as hereinafter defined) based on
substantial equivalence to a device currently in commercial distribution.
1.23 "Foreign Regulatory Agency" shall mean an agency or entity of a
government responsible for approving the marketing, sale and/or distribution of
Program Products in a country other than the United States.
1.24 "Fully Burdened Manufacturing Costs" shall mean ***
1.25 "FUSO Agreement" shall mean the Distribution Agreement dated
August 23, 1988, between i-STAT and FUSO.
1.26 "FUSO Development Agreement" shall mean the Development Agreement
dated August 23, 1988, between i-STAT and FUSO.
1.27 "FUSO License Agreement" shall mean the Manufacturing License
Agreement dated August 23, 1988, between i-STAT and FUSO.
1.28 "HP Agreement" shall mean the Distribution Agreement dated July
28, 1995, between i-STAT and HP.
*** CONFIDENTIAL TREATMENT REQUESTED.
9
9
1.29 "HP Exclusivity Period" shall mean the period under the HP
Agreement during which HP shall have exclusive rights to distribute certain of
i-STAT's products, as determined by Abbott in its sole discretion.
1.30 "HP License Agreement" shall mean the License Agreement dated July
28, 1995, between i-STAT and HP.
1.31 "HP Stock Purchase Agreement" shall mean the Series B Preferred
Stock Purchase Agreement dated as of June 23, 1995, between i-STAT and HP.
1.32 "HP Territory" shall mean the territory into which HP has the
right to distribute certain i-STAT Products pursuant to the HP Agreement, which
territory shall be reduced from time to time pursuant to Section 4.4. As of the
Signing Date, the HP Territory consists of the countries set forth in Schedule
1.32.
1.33 Definition intentionally left blank.
1.34 "i-STAT Know-How and Technology" shall mean i-STAT Products and
i-STAT's or its Affiliates' proprietary sensor and platform technology,
including but not limited to, manufacturing or production techniques,
formulations, methods, products and processes, and any and all patents, patent
applications, Trademarks, trade names, service marks, copyrights, know-how,
Trade Secret, or other proprietary rights of i-STAT and its Affiliates relating
thereto, that are owned or licensed by i-STAT or its Affiliates prior to the
Closing Date or are extensions to i-STAT's and its Affiliates' proprietary
sensor and platform technology developed after the Closing Date in programs not
funded by Abbott.
1.35 "i-STAT Product" shall mean Analyzers, Cartridges and Ancillary
Products, or any combination of the foregoing, in the Field, including the
manuals, labeling, packaging and package inserts thereto. For purposes of this
Agreement, any "New Product" as such term is
10
10
defined under the Marketing and Distribution Agreement in Section 1.55, shall be
deemed to be an i-STAT Product.
1.36 "i-STAT Sensors" shall mean at least one (1) solid state
potentiometric, amperimetric and/or conductometric microsensor device or an
integrated group of such devices designed to detect the presence and/or quantity
of at least one (1) Analyte. ***
1.37 "Milestone" shall mean one (1) of the following events (as more
fully described in Section 2.3) and "Milestones" shall mean two or more of the
following events: First Milestone shall mean ***; Second Milestone shall mean
***; Third Milestone shall mean ***; and Fourth Milestone shall mean ***.
1.38 "Net Sales" shall mean the total of the gross amount billed or
invoiced to Third Parties for the sale of Program Products, less:
(a) Rebates granted and allowances, trade, quantity or cash
discounts actually allowed and taken;
(b) Retroactive price reductions imposed by government
authorities;
(c) Fees, commissions or rebates lawfully paid pursuant to
contracts with group purchasing organizations;
*** CONFIDENTIAL TREATMENT REQUESTED.
11
11
(d) Amounts actually repaid a Third Party by reason of rejection
or return of defective Program Product; and
(e) Upcharges invoiced and paid by Third Parties as part of a
reagent agreement plan or similar arrangement.
1.39 "Party" shall mean i-STAT or Abbott, and "Parties" shall mean
i-STAT and Abbott.
1.40 "Prepayment" shall mean periodic cash payments made by Abbott to
i-STAT which i-STAT shall credit or repay to Abbott in accordance with the terms
and conditions set forth in Section 3.2.
1.41 "Program Budget" shall mean the amount of the i-STAT research
effort that may be available for the R&D Program at ▇▇▇▇▇▇'▇ option. The annual
Program Budget shall be calculated as an amount anywhere in the range from a
minimum of *** to a maximum of *** of the total annual sales of i-STAT Products
and Program Products sold by i-STAT to Abbott and its Affiliates and reviewed
annually by the Parties.
1.42 "Program Patents" shall mean the patents and patent applications
included in Program Technology and set forth on Schedule 1.42. As of the Signing
Date, no Program Patents are on Schedule 1.42. Schedule 1.42 may be amended from
time to time.
1.43 "Program Product" shall mean any product derived from the R&D
Program as specified in a Project Plan.
1.44 "Program Technology" shall mean all inventions, discoveries,
developments, know-how including Trade Secrets (excluding i-STAT Know-How and
Technology and Abbott Know-How and Technology), whether patentable or not, which
are disclosed and/or reduced to practice and that derive from the course of work
performed under the R&D Program.
***CONFIDENTIAL TREATMENT REQUESTED.
12
12
1.45 "Project" shall mean the efforts of the Parties and their
Affiliates relating to a Project Plan for development of a Program Product for
Commercialization.
1.46 "Project Manager" shall be an individual appointed by i-STAT and
approved by the R&D Steering Committee (as set forth in Section 2.2) who is
assigned to a particular Project and who is responsible for coordinating the
efforts of the Project Team.
1.47 "Project Team" shall mean the cross-functional team of individuals
established for development of each Program Product according to a Project Plan
and led by a Project Manager for a given Project.
1.48 "Purchase Price" shall have the meaning set forth in Section 8.2.
1.49 "Regulatory Filing" shall mean an application filed with a
governmental entity for approval by that entity in a country for the sale of a
medical device for human use in such country, such as a 510K Filing.
1.50 "Research and Development Project Plan" or "Project Plan" shall
mean the work program, timetable, Milestones, the quantifiable acceptance
criteria of each Milestone, design goals and Specifications (as hereinafter
defined), listings of appropriate i-STAT Know-How and Technology and appropriate
Abbott Know-How and Technology, estimated budgets and identified
responsibilities of the Parties, and any and all subsequent modifications
thereto, developed by the Project Team, and approved by the R&D Steering
Committee as established for each individual Program Product. The Project Plan
shall be maintained by the Project Manager. The Project Plan may be amended from
time to time by the written mutual agreement of the Parties.
13
13
1.51 "Research and Development Program" or "R&D Program" shall mean the
research and development work funded by Abbott to be carried out by i-STAT
and/or Abbott according to Project Plans for the development and
Commercialization of Program Products according to the tasks, timetables,
Milestones and budgets as set forth in each Project Plan. The Parties intend
that the scope of the work performed under the R&D Program will be specific to
the intended application of the Program Product. The Parties do not intend to
include work on i-STAT Know-How and Technology which will be funded by i-STAT,
or work on Abbott Know- How and Technology which will be funded by Abbott.
1.52 "Signing Date" shall mean the last date on which a Party executes
this Agreement.
1.53 "Specifications" shall mean the Program Product(s)'
characteristics established by the Project Team and approved by Abbott in
writing, and maintained by the Project Manager.
1.54 "Starting Date" shall mean January 1, 1999, unless an earlier date
is mutually agreed upon in writing by the Parties; provided, however, the
Starting Date shall not occur unless the Closing first has occurred.
1.55 "Term" shall mean the period of time beginning on the Closing Date
and continuing, unless earlier terminated pursuant to Section 9.2, until the
expiration or termination of the Marketing and Distribution Agreement. Term
shall not mean the duration of any license or grant of rights hereunder the
expiration of which shall be separately specified.
1.56 "Territory" shall mean the entire world, except for the
Co-exclusive FUSO Territory, and the HP Territory, subject to the Co-exclusive
FUSO Territory and/or the HP Territory, or portions thereof, becoming part of
the Territory pursuant to Section 4.4.
14
14
1.57 "Third Party" means a natural person, corporation, partnership,
trust, joint venture, governmental authority or other legal entity or
organization other than the Parties and/or their Affiliates.
1.58 "Trademarks" shall mean the trademarks of either Party used to
co-label Program Products and attached hereto as Schedule 1.58.
1.59 "Trade Secrets" shall mean the technical or nontechnical data,
formulae, patterns, compilations, programs, devices, methods, techniques,
drawings, processes, financial data, financial plans, marketing plans, product
plans and the like, owned or licensed by a Party and/or its Affiliates: (a) from
which a Party and/or its Affiliates derives an actual or potential economic
value by being held in secrecy and not known by Third Parties who are not under
an obligation of confidentiality with respect thereto; or (b) which gives such
Party an advantage over Third Party competitors who do not know or use it.
1.60 "United States" shall mean the fifty (50) states of the United
States, including its territories and possessions, the District of Columbia and
Puerto Rico.
ARTICLE 2. JOINT RESEARCH AND DEVELOPMENT PROGRAM
2.1 R&D Steering Committee. Each Party shall designate two (2)
representatives to serve on an R&D Steering Committee. The R&D Steering
Committee shall be responsible for determining the Program Budget available for
research and development of Program Products. In addition, the R&D Steering
Committee shall review prioritization of Projects and allocation of budgeted
funds to the individual Projects, approve Project Plans, recommend the
initiation of
15
15
Projects, approve Project Managers, monitor the progress of Projects against
budgets, timelines and Milestones, and approve recommendations for prosecuting
Program Patents included in Program Technology. Notwithstanding the joint nature
of these activities, Abbott shall have the final authority for Project
prioritization, budget allocations, date of Project Initiation and final
Specifications for each Project.
2.2 Project Team. Each Program Product shall be developed by a Project
Team which shall include representatives from both Parties, as mutually agreed
by the Parties. i-STAT shall have the responsibility for nominating a Project
Manager to coordinate the efforts of the Project Team, and the R&D Steering
Committee shall have final approval for the Project Manager. The Project Team
shall be responsible for developing and recommending a Project Plan to the R&D
Steering Committee and leading the development tasks necessary to Commercialize
each Program Product as stated in the Project Plan. The Project Plan shall
include, but shall not be limited to, timelines, budgets, assignment of
responsibilities and performance specifications. The performance specifications
shall include both target and minimally acceptable performance specifications
for the Research and Development Prototype, the 510K Filing data set and the
final Program Product in a quantitative and measurable manner. The Project Team
shall recommend to the R&D Steering Committee whether to pursue patent
protection for Program Technology resulting from the Project.
2.3 Project Plan Milestones. The Project Team shall establish specific
criteria for the measurement of the following four (4) Milestones:
(a) First Milestone: ***.
*** CONFIDENTIAL TREATMENT REQUESTED.
16
16
(b) Second Milestone: ***;
(c) Third Milestone: ***
(d) Fourth Milestone: ***
2.4 Discontinuance of Project. Abbott, in its sole discretion, may
discontinue a Project at any time during such Project. Abbott shall pay i-STAT
the Actual Costs due to i-STAT up to the date upon which i-STAT is notified in
writing such Project is terminated by Abbott. i-STAT shall have the right, but
not the obligation, to take over the Project and provide the necessary funding
for the Project from that point forward. If i-STAT elects to continue the
Project, i-STAT shall develop and solely fund the Project. Abbott shall retain
the exclusive right
*** CONFIDENTIAL TREATMENT REQUESTED.
17
17
to Commercialize a product resulting from such a Project and such product will
be deemed as an i-STAT Product in the Field, pursuant to the Marketing and
Distribution Agreement.
2.5 Regulatory Filings. The Parties shall meet and discuss the
countries in which to seek regulatory approval and shall mutually agree upon the
strategy to expedite such approval and market entry, including ownership of the
regulatory filing.
ARTICLE 3. DUE DILIGENCE OF THE PARTIES
3.1 ▇▇▇▇▇▇'▇ General Responsibilities. ▇▇▇▇▇▇'▇ responsibilities shall
include, as appropriate:
(a) Identifying and selecting Program Products after discussing
with i-STAT the feasibility of developing such a Program
Product. As of the Signing Date, Abbott has identified the
following candidate Program Products: ***;
(b) Approving the final design goals and Specifications of each
Project Plan established for each Program Product by a Project
Team;
(c) Providing appropriate Abbott Know-How and Technology for
utilization in the R&D Program;
(d) Considering the recommendations of the R&D Steering Committee
and the Project Teams with regard to Project Plans and patent
procurement;
*** CONFIDENTIAL TREATMENT REQUESTED.
18
18
(e) Using reasonable commercial efforts to diligently undertake,
pursue and support all research activities that are required
to complete the R&D Program and all Project Plans; and
(f) Providing guidance to i-STAT regarding requirements for
Regulatory Filings.
3.2 Payments. Abbott shall reimburse i-STAT for i-STAT's Actual Cost of
the work performed according to the Project Plan. The payments shall be made as
follows: Upon the date of *** (Milestone 1), Abbott shall make a Prepayment to
i-STAT which shall be the estimated budget for the first Calendar Quarter's
expenses of the Project. At the end of each Calendar Quarter, i-STAT shall
submit an invoice, in sufficient detail to facilitate proper review and approval
by Abbott, for all Actual Costs for the Calendar Quarter as well as major
activities or tasks completed. The invoice for the Project's actual first
Calendar Quarter submitted by i-STAT to Abbott shall be compared to the
Prepayment made by Abbott, with the difference either submitted to i-STAT (if
the first Calendar Quarter Actual Cost is higher than the Prepayment), or
credited to Abbott against future payments to be made by Abbott (if the
Prepayment is higher than the first Calendar Quarter's Actual Costs); such
difference shall be paid to i-STAT or credited to Abbott within thirty (30) days
of performing such calculation. Subsequent invoices for each Calendar Quarter's
Actual Cost will be submitted by i-STAT and be subject to review by Abbott, with
payment made to i-STAT within thirty (30) days of receipt and review of such
invoice. Abbott shall have the right to audit i-STAT's books for confirmation of
Actual Costs as set forth in Section 3.4. If Abbott terminates the Project,
i-STAT shall be reimbursed for expenses only up to the date i-STAT is notified
of ▇▇▇▇▇▇'▇ termination.
*** CONFIDENTIAL TREATMENT REQUESTED.
19
19
3.3 i-STAT's General Responsibilities. i-STAT's responsibilities shall
include, as appropriate:
(a) Providing assistance and advice to Abbott to determine Program
Products;
(b) Performing technical research and development work at its
facilities in connection with and according to the Project
Plan;
(c) Incorporating appropriate i-STAT Know-How and Technology for
development and manufacture of Program Products under the R&D
Program;
(d) Using reasonable commercial efforts to diligently undertake,
pursue and support all research activities that are required
to complete the R&D Program and all Project Plans;
(e) Maintaining proper books and records regarding Actual Costs
and Fully Burdened Manufacturing Costs, as set forth in
Section 3.4; and
(f) Committing to providing Abbott with priority equal to i-STAT's
highest priority for research and development work on every
Project, up to the allocated amount of the Program Budget.
3.4 Records and Audits. i-STAT shall maintain proper books and records
in accordance with generally accepted accounting principles reflecting all
information necessary for the accurate calculation of Actual Cost, Fully
Burdened Manufacturing Cost, and other calculations necessary and appropriate to
determine Purchase Price of Program Products. Upon thirty (30) days' prior
written notice to i-STAT (but not more frequently than once in any Contract
Year, unless there is a dispute, then as frequently as is necessary), Abbott may
retain, at ▇▇▇▇▇▇'▇ expense, an independent certified public accountant
reasonably acceptable to i-STAT to examine i-STAT's books and records relating
to the matters described herein, which shall be
20
20
transferred to, if not already at, i-STAT's principal place of business. Such
examination shall occur during normal business hours for the sole purpose of
verifying the accuracy of i-STAT's calculations. Such accountant shall be
required to execute a mutually acceptable confidentiality agreement and shall
report to Abbott only the amount of any discrepancy in the calculations. Within
thirty (30) days after completion of such examination, the Parties shall
reconcile any underpayment or overcharge, if any, by credit or debit memo;
provided, however, if such adjustment is to occur at the end of a Contract Year,
any overpayment or underpayment shall be paid by check or wire transfer to
Abbott within thirty (30) days after the end of the final reconciliation. Such
examination rights may be exercised by Abbott only with respect to records for
the then current Contract Year and the then prior Contract Year.
3.5 Delays. Any delay in or failure to complete any Project Plan
according to the Project Plan's design goals, Specifications and timelines shall
neither constitute a failure of diligence by i-STAT nor a breach by i-STAT of
this Agreement unless due to either the gross negligence or willful misconduct
of i-STAT.
ARTICLE 4. OWNERSHIP OF TECHNOLOGY
4.1 Program Technology. All Program Technology invented either solely
or jointly by the Parties shall be owned jointly by the Parties.
4.2 Ownership of i-STAT Know-How and Technology. All i-STAT Know-How
and Technology shall be the sole property of i-STAT. i-STAT shall have no
obligation hereunder to license i-STAT Know-How and Technology to ▇▇▇▇▇▇.
21
21
4.3 Ownership of ▇▇▇▇▇▇ Know-How and Technology. All ▇▇▇▇▇▇ Know-How
and Technology shall be the sole property of ▇▇▇▇▇▇. ▇▇▇▇▇▇ shall ▇▇▇▇▇ a
license to i-STAT under appropriate ▇▇▇▇▇▇ Know-How and Technology as identified
in a Project Plan, only for the limited purpose of manufacturing Program
Products for ▇▇▇▇▇▇, for i-STAT or Third Parties only as expressly provided in
this Agreement.
4.4 Right to Commercialize Program Products in the Territory. During
the Term of this Agreement, ▇▇▇▇▇▇ and its Affiliates shall have the sole and
exclusive right to Commercialize Program Products in the Territory in the Field.
4.4.1 Right to Commercialize Program Products in the Co-Exclusive FUSO
Territory. During the Term, ▇▇▇▇▇▇ and its Affiliates (and not i-STAT nor its
Affiliates) shall have the right to Commercialize Program Products in the Field
in the Co-Exclusive FUSO Territory. ▇▇▇▇▇▇ and its Affiliates shall not have the
obligation to sublicense any right to Program Products to any Third Party in the
Field in the Co-exclusive FUSO Territory. If the last to expire of the FUSO
Agreement, FUSO Development Agreement and FUSO License Agreement expires during
the Term, (and i-STAT shall so notify ▇▇▇▇▇▇) then i-STAT shall have the right
to Commercialize Program Products outside the Field in the Co-Exclusive FUSO
Territory.
4.4.2 HP Territory. As of the expiration of the HP Exclusivity Period
(and i-STAT shall so notify ▇▇▇▇▇▇), ▇▇▇▇▇▇ and its Affiliates shall have the
sole and exclusive right to Commercialize Program Products in the Field in the
HP Territory.
4.4.3 Other Distributors. In the event that an issue arises in any
Distributor Territory regarding the Commercialization of Program Products, the
Parties shall discuss in good faith a resolution to such issue in a manner
consistent with the provisions of this Agreement.
22
22
ARTICLE 5. LICENSES
5.1 General. During the Term, ▇▇▇▇▇▇ shall have the exclusive and sole
right to Commercialize Program Products in the Field in the Territory. Neither
Party shall have the right to Commercialize Program Products in the HP Territory
while the HP Exclusivity Period is in effect. ▇▇▇▇▇▇, but not i-STAT, shall have
the right to Commercialize Program Products in the Co-exclusive FUSO Territory.
Neither Party shall have the right to grant a license or in any other way convey
to Third Parties any of its rights to Program Technology in the Field in the
Territory, including the HP Territory, without the express written consent of
the other Party. Each Party shall have the right to Commercialize Program
Products outside of the Field in the Territory. Each Party may grant Third
Parties the right to Commercialize the Program Products outside the Field in the
Territory with the express written consent of the other Party, which consent
shall not be withheld unreasonably. At termination of this Agreement, i-STAT
shall have the right: (a) to Commercialize Program Products in the Field in the
Territory according to the terms set forth in Section 8.4; and (b) to
Commercialize Program Products outside the Field. ▇▇▇▇▇▇ has a right to
Commercialize Program Products through sub-distributors, and nothing contained
in this Agreement shall be construed to limit ▇▇▇▇▇▇'▇ right to do so.
5.2 Rights of the Parties to License Third Parties.
5.2.1 Neither Party shall have the right to license in whole
or in part Program Technology to a Third Party in the Field in the Territory
including the HP Territory without the express written consent of the other
Party.
23
23
5.2.2 Neither Party shall have the right to license Program
Technology to Third Parties outside of the Field in the Territory without the
express written consent of the other Party, which consent shall not be withheld
unreasonably.
5.2.3 These sublicense restrictions set forth this section 5.2
shall survive termination or expiration of this Agreement as described in
Article 9.
5.2.4 It is understood and agreed by the Parties that an
original equipment manufacturer or private label manufacturer shall be
considered a sublicensee for purposes of this Agreement.
5.2.5 During the HP Exclusivity Period, neither Party shall
have the right to license or otherwise convey rights to Third Parties to Program
Technology in the HP Territory.
5.3 Rights of the Parties to Grant Rights to Commercialize Program
Products to Third Parties.
5.3.1 Neither Party shall have the right to grant the right to
Commercialize Program Products to a Third Party in the Field in the Territory,
including the HP Territory, without the express written consent of the other
Party.
5.3.2 Neither Party shall have the right to grant the right to
Commercialize Program Products to Third Parties outside of the Field in the
Territory without the express written consent of the other Party, which consent
shall not be withheld unreasonably.
5.3.3 The restrictions set forth in this Section 5.3 shall
survive termination or expiration of this Agreement as described in Article 9.
5.3.4 During the HP Exclusivity Period, neither Party shall
have the right to grant rights to a Third Party to Commercialize the Program
Products in the HP Territory.
24
24
5.4 License to ▇▇▇▇▇▇ Technology and Know-How. In the event that,
during the Term, i-STAT requests a non-exclusive license with no right to
sublicense to utilize ▇▇▇▇▇▇ Technology and Know-How incorporated into a Program
Product to Commercialize a Program Product outside the Field, ▇▇▇▇▇▇ shall ▇▇▇▇▇
such right to i-STAT, which ▇▇▇▇▇▇ shall do unless ▇▇▇▇▇▇ is prohibited from
doing so by an agreement with a Third Party. i-STAT shall pay a royalty to
▇▇▇▇▇▇ at the rate of *** of Net Sales of such Program Product sold by i-STAT
and its Affiliates outside the Field. i-STAT's royalty obligation for ▇▇▇▇▇▇
Know-How and Technology shall continue until: ***
i-STAT's obligation to pay ▇▇▇▇▇▇ a royalty pursuant to this Section 5.4 shall
survive the expiration or termination of this Agreement, except as provided in
Section 9.3(f).
5.5 ▇▇▇▇▇▇'▇ Right To Commercialize Program Product Outside the Field.
In the event that, during the Term, ▇▇▇▇▇▇ requests a non-exclusive right to
Commercialize a Program Product outside the Field, i-STAT may grant such license
to ▇▇▇▇▇▇, which i-STAT shall do unless prohibited from doing so by an agreement
with a Third Party.***.
5.6 No Right to ▇▇▇▇▇▇'▇ Proprietary Sensor Technology. In no event
shall any term or provision in this Agreement be interpreted to grant i-STAT or
its Affiliates a license to ▇▇▇▇▇▇'▇ or its Affiliates' proprietary sensor
technology, or confer any commercial or
*** CONFIDENTIAL TREATMENT REQUESTED.
25
25
manufacturing right to i-STAT or its Affiliates to ▇▇▇▇▇▇'▇ or its Affiliates'
proprietary sensor technology.
ARTICLE 6. PATENT PROSECUTION AND ENFORCEMENT OF JOINTLY OWNED
PROGRAM TECHNOLOGY
6.1 Patent Prosecution. The R&D Steering Committee shall be responsible
for recommending to ▇▇▇▇▇▇ that the Parties seek patent protection for Program
Technology in the name of both Parties as assignees on all inventions,
regardless of inventorship. After receiving a written recommendation from the
R&D Steering Committee, ▇▇▇▇▇▇ shall notify i-STAT in writing whether ▇▇▇▇▇▇
agrees to pursue patent protection for any such recommended Program Technology,
and shall indicate to i-STAT in which countries ▇▇▇▇▇▇ desires to seek such
protection. ▇▇▇▇▇▇ then shall be solely responsible for: (a) filing, prosecuting
and maintaining U.S. rights and foreign applications and patents covering such
Program Technology; and (b) all costs incurred in connection with such
responsibility. ▇▇▇▇▇▇ shall keep i-STAT advised as to all material developments
with respect to all Program Patents, and shall supply i-STAT with copies of all
papers received, solicit i-STAT's comments to the papers, and prepare and then
copy i-STAT on any papers proposed to be filed in connection with the
prosecution or defense thereof in a sufficiently reasonable time for i-STAT to
submit its further comments to ▇▇▇▇▇▇. All comments provided by i-STAT to ▇▇▇▇▇▇
shall be reviewed and shall not be unreasonably rejected by ▇▇▇▇▇▇. ▇▇▇▇▇▇ shall
use its reasonable good judgment when pursuing patent protection for Program
Patents. ▇▇▇▇▇▇ shall have the right to designate counsel of its choice to
perform any or all such related work.
6.2 Discontinuance of Patent Prosecution. If ▇▇▇▇▇▇ decides not to
follow the R&D Steering Committee's recommendations to prepare and file a patent
application covering a particular
26
26
aspect of Program Technology or otherwise seek patent rights to a particular
aspect of Program Technology under Section 6.2, or if ▇▇▇▇▇▇ elects to
discontinue the prosecution or maintenance of any Program Patent, ▇▇▇▇▇▇ shall
promptly notify i-STAT. i-STAT may, but shall not have the obligation to, file
or continue prosecution of such patent application included in Program Patents
or maintain such Program Patent, at its own expense in the name of both Parties.
6.3 Infringement by Third Parties. In the event a Party has reason to
believe that a Third Party may be infringing any of the Program Patents included
in Program Technology in the Field by the Third Party's manufacture, sale, use
or importation of an infringing product in the Field in the Territory, such
Party shall promptly notify the other Party. ▇▇▇▇▇▇ may, in its sole discretion,
elect to enforce any Program Patent included in Program Technology through legal
action or otherwise, and i-STAT agrees to reasonably cooperate with ▇▇▇▇▇▇ in
such enforcement. In the event that ▇▇▇▇▇▇ requests the assistance of i-STAT and
i-STAT requires the assistance of patent counsel, i-STAT shall so advise ▇▇▇▇▇▇
promptly and, after ▇▇▇▇▇▇'▇ approval, i-STAT shall have the right to retain
patent counsel of its choice at ▇▇▇▇▇▇'▇ expense; provided, however, that ▇▇▇▇▇▇
shall have the right to review all invoices associated therewith, and
discontinue such patent counsel assistance immediately upon notice to i-STAT
hereunder. ▇▇▇▇▇▇ shall be responsible for any costs associated with such suit
and/or settlement, and shall be entitled to retain any recovery that may be
obtained in any suit brought by ▇▇▇▇▇▇. If such settlement involves any material
admission(s) by ▇▇▇▇▇▇ relating to such suit, ▇▇▇▇▇▇ shall use its reasonable
best efforts to ensure the confidential treatment of all its material
admissions. ▇▇▇▇▇▇ hereby agrees that it shall not make any material admission
relating to i-STAT Know-how and Technology without the prior written consent of
27
27
i-STAT, which consent shall not be withheld unreasonably. In the event ▇▇▇▇▇▇
does not commence activities to enforce diligently such Program Patent within
three (3) months after notice of possible infringement is given between i-STAT
and ▇▇▇▇▇▇, i-STAT may institute suit and diligently pursue such suit. ▇▇▇▇▇▇
agrees to serve as a nominal party if its presence is legally required and to
sign any papers necessary to support any litigation. i-STAT shall be entitled to
retain any recovery which may be obtained in any suit brought by i-STAT. ▇▇▇▇▇▇
shall provide reasonable cooperation with respect to any suit which i-STAT may
bring pursuant to this Section 6.3. i-STAT hereby agrees that it shall not make
any material admissions relating to ▇▇▇▇▇▇ Know-how and Technology without the
prior written consent of ▇▇▇▇▇▇, which consent shall not be withheld
unreasonably.
6.4 Third Party Claims for Infringement. If a Third Party brings a
legal action or administrative proceeding against either or both of the Parties
alleging infringement by a Program Product in the Field in the Territory, the
Parties agree that they shall confer in good faith to determine the most
effective means of cooperating to defend their sole and mutual interests. Each
Party shall bear its own expenses related to the defense unless otherwise agreed
at the time.
If it is clear that the predominant aspect of the Program Product at
issue was contributed by one Party rather than the other, then the contributing
Party will be financially responsible for any judgment and have the first right
to take the lead in the coordinated defense.
If it is not clear that the aspect of the Program Product at issue was
contributed by one Party rather than the other, then the Parties will share
equally in any judgment and negotiate in good faith as to which Party takes the
lead in the coordinated defense.
In any event with respect to each such legal action or administrative
proceeding:
28
28
(a) Neither Party shall have the right to enter into any
financial, commercial or other settlement with such Third
Party without the consent of the other Party, which consent
shall not be withheld unreasonably.
(b) Neither Party shall have the right to make any adverse
admissions relating to infringement without the consent of the
other Party, which consent shall not be withheld unreasonably.
(c) Each Party, upon notice to the other Party, shall have the
right to mitigate potential damages as such Party deems
appropriate, including, without limitation, stopping the
manufacture of the alleged infringing Program Product,
stopping Commercialization of such alleged infringing Program
Product, redesigning the alleged infringing Program Product or
action and reconfiguring the alleged infringing Program
Product or action. Any such mitigation taken by a Party shall
not be used against that Party when determining that Party's
performance under the Agreement. Any lead taken by a Party
under this Section 6.4 relating to defending the other Party
in such legal action or administrative proceeding shall not be
used against the non-lead Party when determining the non-lead
Party's performance under this Agreement. Only if a Party
fails to perform its obligations under this Section 6.4 shall
the other Party be entitled to indemnification for such
obligations pursuant to the provisions of Article 13.
29
29
ARTICLE 7. TRADEMARKS
7.1 Trademark License. i-STAT hereby grants to ▇▇▇▇▇▇ and its
Affiliates a non-exclusive license, with the right to sublicense, to use
i-STAT's Trademarks to Commercialize Program Products, in the Field in the
Territory. Pursuant to Section 13.1 of the Marketing and Distribution Agreement,
on or before January 1 of each Contract Year, i-STAT shall provide ▇▇▇▇▇▇ with a
Trademark report reflecting all applications for Trademarks and the status
thereof. In addition, i-STAT shall, at its expense, file new applications to
register any or all of the i-STAT's Trademarks in any or all of the countries in
the Territory, as may be reasonably requested by ▇▇▇▇▇▇. ▇▇▇▇▇▇ shall give
i-STAT at least ninety (90) days' prior written notice before Commercializing
any Program Product under i-STAT's Trademarks in any country not identified in
i-STAT's Trademark report. The Parties shall mutually agree on the trademark
approach in any such country, taking into consideration, among other things, the
length of time required to obtain trademark registration, laws relating to
trademark use, the existence of any conflicting trademark registrations,
applications or uses and anticipated sales volumes of the relevant Program
Products in such country. Any use of an ▇▇▇▇▇▇ Trademark by i-STAT shall be
subject to ▇▇▇▇▇▇'▇ prior approval, which approval may be withheld by ▇▇▇▇▇▇ at
▇▇▇▇▇▇'▇ sole discretion.
7.2 Ownership. It is understood and agreed that i-STAT is the sole and
exclusive owner of all right, title and interest in and to i-STAT's Trademarks.
Nothing contained in this Agreement shall be construed as an assignment to the
non-owning Party of any right, title or interest in i'STAT's Trademarks; it
being understood that all rights, title and interests relating to such
Trademarks are expressly reserved by i-STAT, except for the rights being
licensed hereunder.
30
30
7.3 Infringement. Each Party shall notify the other Party of any
suspected infringements by Third Parties of the Trademarks in the Field that may
come to a Party's attention. Each Party shall have the initial right to
determine whether any action shall be taken due to any such infringement of its
Trademark. Each Party shall have the right to employ counsel of its choosing and
to direct the handling of the litigation and any settlements thereof with
respect to its own Trademarks. In the event i-STAT does not pursue such
potential infringement within three (3) months after notice of such potential
infringement, ▇▇▇▇▇▇ shall have the right to take action on its own behalf, to
employ counsel of its choosing and to direct the handling of the litigation and
any settlement thereof, at ▇▇▇▇▇▇'▇ own expense. The Parties agree to cooperate
with each other in maintaining, protecting and defending its Trademarks.
7.4 Co-Labeled Product. i-STAT covenants and agrees that it shall sell
Program Products identified by an ▇▇▇▇▇▇ Trademark or ▇▇▇▇▇▇ trade name only to
▇▇▇▇▇▇ and its Affiliates or to an ▇▇▇▇▇▇-appointed sub-distributor.
ARTICLE 8. COMMERCIALIZATION OF PROGRAMS PRODUCTS
8.1 Program Products in the Program Field. ▇▇▇▇▇▇ and its Affiliates
shall have the sole, exclusive right, including the right to appoint
sub-distributors, to Commercialize Program Products in the Field for use in the
Territory. ▇▇▇▇▇▇ and its Affiliates (and not i-STAT nor its Affiliates) shall
have the right to Commercialize Program Products in the Field in the
Co-exclusive FUSO Territory. ▇▇▇▇▇▇ and its Affiliates shall not have the
obligation to sublicense any right to Program Products to any Third Party in the
Field in the Co-Exclusive FUSO Territory. If the last of the
31
31
FUSO Agreement, FUSO Development Agreement and FUSO License Agreement expires
during the Term, then i-STAT shall have the right to Commercialize Program
Products outside the Field in the Co-Exclusive FUSO Territory. Neither Party
shall have the right to Commercialize Program Products in the Field in the HP
Territory, except as provided in Section 4.4. i-STAT shall manufacture ▇▇▇▇▇▇'▇
and its Affiliates' requirements of Program Products according to the terms and
conditions set forth in the Marketing and Distribution Agreement, except as
expressly provided in this Agreement. If any term or condition of this Agreement
is inconsistent with a similar term in the Marketing and Distribution Agreement
with regard to Program Products, the term or condition of this Agreement shall
prevail.
8.2 Purchase Price of Program Products.
8.2.1 Regular Purchase Price. ▇▇▇▇▇▇ shall pay i-STAT a
Purchase Price for each Program Product sold to ▇▇▇▇▇▇, in accordance with
pricing provisions set forth in the Marketing and Distribution Agreement except
as provided in Section 8.2.2.
8.2.2 Credit for ▇▇▇▇▇▇'▇ Funding of the R&D Program. During
the period that the funding for the Project that developed the Program Product
has not been repaid to ▇▇▇▇▇▇ in the amount specified in Section 8.2.3 hereof,
the Purchase Price for that Program Product shall be determined according to the
following provisions. The Purchase Price shall be ***. This difference shall be
credited to ▇▇▇▇▇▇ to reimburse ▇▇▇▇▇▇ for its funding of the development of
that Program Product, pursuant to Section 8.2.3.
8.2.3 Computation of R&D Funding Reimbursement. ▇▇▇▇▇▇ shall
fund each R&D Program pursuant to Section 3.2. ▇▇▇▇▇▇ shall accrue the amount so
paid to i-STAT. The amount
*** CONFIDENTIAL TREATMENT REQUESTED.
32
32
paid to i-STAT shall accrue interest at the rate of ***. The amount to be
reimbursed to ▇▇▇▇▇▇ for the Project that developed that Program Product shall
be the total of the amount paid by ▇▇▇▇▇▇ to fund that Project plus the interest
on that amount as set forth in this Section 8.2.3.
8.3 Program Products Outside the Field. Each Party shall have the right
to Commercialize Program Products outside the Field. ***
8.4 i-STAT's Rights to Commercialize Program Products in the
Field.
At termination of this Agreement as set forth in Sections 9.1 and 9.2,
i-STAT shall have the right to Commercialize Program Products in the Field
directly to end-users in the Territory and not through any distributor or Third
Party. In the event that i-STAT so elects to Commercialize a Program Product in
the Field, i-STAT shall pay to ▇▇▇▇▇▇ a royalty of *** of Net Sales of such
Program Product sold by i-STAT and its Affiliates in the Field in the Territory
***.
*** CONFIDENTIAL TREATMENT REQUESTED.
33
33
ARTICLE 9. TERM AND TERMINATION
9.1 Term. This Agreement shall commence on the Closing Date, and unless
sooner terminated pursuant to Section 9.2, shall continue in effect until the
expiration or termination of the Marketing and Distribution Agreement. Term
shall not mean the duration of any license or grant of rights hereunder, the
expiration of which, if any, shall be separately specified.
9.2 Early Termination. This Agreement may be terminated in accordance
with the following provisions:
9.2.1 For No Cause By ▇▇▇▇▇▇. For no cause by termination of the
Agreement:
(a) at any time prior to the Date of First Market Launch of the
first Program Product upon sixty (60) days' prior written
notice from ▇▇▇▇▇▇ to i-STAT; or
(b) at any time after the Date of First Market Launch of a Program
Product upon one hundred twenty (120) days' prior written
notice from ▇▇▇▇▇▇ to i-STAT.
9.2.2 Termination for Cause.
(a) Bankruptcy; Material Breach. Either Party may terminate this
Agreement for cause upon written notice to the other Party in
the event the other Party: (a) appoints a receiver, executes
an assignment for the benefit of creditors or files or
otherwise
***CONFIDENTIAL TREATMENT REQUESTED.
34
34
becomes subject to bankruptcy or insolvency
proceedings; or (b) materially breaches this
Agreement and fails to cure such breach within sixty
(60) days after written notice of breach from the
non-breaching Party, as such cure period may be
extended for such additional period as the
non-breaching Party reasonably determines that the
breaching Party is diligently pursuing a cure of such
breach.
(b) Uncured Material Breach.
(i) ▇▇▇▇▇▇ may terminate this Agreement
for cause upon an uncured material
breach of a warranty or
representation by i-STAT of this
Agreement as set forth in Sections
12.1 and 12.3; or
(ii) i-STAT may terminate this Agreement
upon an uncured material breach of a
warranty or representation by ▇▇▇▇▇▇
as set forth in Sections 12.2 and
12.3.
(c) Delay of Closing. This Agreement may be terminated,
and the transactions contemplated abandoned, by
either Party by written notice to the other Party if
the Closing Date does not occur on or before the date
which is one hundred and thirty (130) days from the
Signing Date.
(d) By ▇▇▇▇▇▇ for Change of Control. ▇▇▇▇▇▇ shall have
the right to terminate this Agreement upon twelve
(12) months' prior written notice to i-STAT in the
event of a Change of Control of i-STAT.
(e) Non-Fulfillment of Conditions. The non-fulfillment of
any of the conditions described in Article 14
(whether or not the Closing occurs) shall not
35
35
result in any liability to any Party unless such
non-fulfillment is a result of a breach of this
Agreement or any of the other Alliance Agreements by
such Party.
9.3 Consequences of Expiration or Termination.
9.3.1 On the date of expiration of the Term or early
termination of this Agreement by either Party:
(a) ▇▇▇▇▇▇'▇ obligation to pay for costs of filing patent
applications and patent maintenance of Program
Products under Section 6.1 shall cease;
(b) The Parties shall retain joint ownership of Program
Patents included in Program Technology, joint data
and joint information;
(c) ▇▇▇▇▇▇'▇ right to Commercialize the Program Products
in the Field and outside of the Field shall survive;
(d) i-STAT shall have the right to sell directly to end
users Program Product in the Field in the Territory,
as set forth in Section 8.4 and outside the Field as
set forth in Section 5.1;
(e) If termination was due to a breach of a
representation or warranty under Article 12, then the
non-breaching Party also shall have any remedy under
Article 13;
(f) If i-STAT terminates due to an uncured material
breach by ▇▇▇▇▇▇, i-STAT's obligation to pay
▇▇▇▇▇▇'▇ development expenses and royalties pursuant
to Section 8.4 shall survive. Notwithstanding the
above, if i-STAT terminates due to an uncured
material breach by ▇▇▇▇▇▇ of its obligations of
confidentiality regarding i-STAT's information as set
forth in Article 10, i-STAT shall not be required to
pay royalties pursuant to Section 8.4 for any Program
Products that materially
36
36
incorporate such i-STAT Confidential Information
included in such material breach by ▇▇▇▇▇▇.
9.3.2 Within sixty (60) days of the date of expiration of the
Term under Section 9.1 or early termination by either Party as set forth in
Section 9.2, each Party shall, except as otherwise provided in this Agreement,
return or destroy all Confidential Information of the other Party; except that
each Party may retain one (1) copy of Confidential Information for archival
purposes solely to confirm compliance with the provisions of Article 10.
9.3.3 Either Party may terminate this Agreement in the event a
force majeure event continues for one hundred eighty (180) consecutive days and
prevents a Party from materially performing its obligations under this
Agreement. Such termination shall not be considered a breach by either Party.
9.3.4 Termination, expiration, cancellation or abandonment of
this Agreement through any means and for any reason shall not relieve the
Parties of any obligation accruing prior thereto and shall be without prejudice
to the rights and remedies of either Party with respect to any antecedent breach
of any of the provisions of this Agreement.
9.3.5 Notwithstanding the terms and conditions of Section
9.2.2(a), neither Party shall be obligated to terminate this Agreement in the
event the other Party materially breaches this Agreement. The non-breaching
Party shall have the right to seek, in accordance with Section 15.5, other
remedies available to it at law and equity to recover for such breach, without
having to terminate this Agreement.
9.4 Survival. Expiration or early termination of this Agreement shall
not relieve either Party of its obligations incurred prior to expiration or
early termination. The following provisions shall
37
37
survive expiration or early termination of this Agreement or of any extensions
thereof: Article 1 (Definitions); Section 3.2 (Payments); Section 3.4 (Records
and Audit); Article 4 (Ownership Technology); Article 5 (Licenses); Sections 6.3
and (Third Party Infringement), 6.4; Sections 7.2 and 7.4 (Trademarks); Article
8 (Commercialization of Program Products); Sections 9.3 (Consequences of
Expiration or Early Termination) and 9.4 (Survival); Article 10 (Confidential
Information and Trade Secrets, as to the obligations of the Parties); Section
10.5 (Public Announcements); Article 11 (Non-Competition); Article 12
(Representations and Warranties); Article 13 (Indemnification as to events
giving rise to indemnification that occurred prior to termination only); Section
15.4 (Binding Effect); Section 15.5 (Dispute Resolution) Section 15.12
(Governing Law), Section 15.11 (Entire Agreement). In addition, all license
provisions that survive termination, that are irrevocable or that arise due to
termination shall survive in accordance with their terms. Notwithstanding the
above, any other provisions of this Agreement contemplated by their terms to
pertain to a period of time following termination or expiration of this
Agreement shall survive for the specified period of time only.
ARTICLE 10. CONFIDENTIAL INFORMATION
10.1 Confidentiality. The Parties acknowledge that during the term each
of them and their Affiliates will exchange Confidential Information (including
i-STAT Know-How and Technology and Abbott Know-How and Technology) pertaining to
their performance hereunder, and the disclosure and use of any such Confidential
Information shall be governed by the provisons of this Article 10 and not by the
provisions of the Confidentiality and Stand Still Agreement between the Parties,
dated March 11, 1998. Each Party shall use Confidential Information of the other
Party only for the purpose of the activities contemplated by this Agreement and
shall not disclose such Confidential Information to a Third Party except in
accordance with the provisions of this
38
38
Agreement. The Parties shall ensure that their Affiliates keep all Confidential
Information exchanged hereunder confidential in accordance with the provisions
hereof as though the Affiliates were parties hereto. This provision shall remain
in effect for the term of this Agreement and for a period of three (3) years
after termination or expiration of this Agreement for all Confidential
Information excluding Trade Secrets. Trade Secrets shall be kept confidential by
the Receiving Party according to the terms set forth in Section 10.2.
10.2 Handling of Trade Secrets. During the course of its performance
hereunder, a Party (the "Disclosing Party") may desire or be requested to
disclose Confidential Information to the other Party (the "Receiving Party")
which the Disclosing Party considers a Trade Secret. In such event, the
Disclosing Party first shall inform the Receiving Party, on a non-confidential
basis, of the general nature of the Trade Secret information. The Receiving
Party shall have ten (10) days to decide whether it wishes to have such Trade
Secrets disclosed to it and to inform the Disclosing Party in writing that it
wishes to receive such a disclosure. Any Trade Secrets so disclosed between the
Parties shall be marked "Trade Secret" and the Receiving Party shall not
disclose or use such Trade Secret except as expressly permitted under this
Agreement for the Term of this Agreement and thereafter. In the event that the
Disclosing Party discloses Trade Secrets to the Receiving Party without written
approval of the Receiving Party and/or without appropriately marking such
information as "Trade Secret," that Trade Secret shall be handled as
Confidential Information under Section 10.1
10.3 Permitted Disclosures. Notwithstanding, the above, nothing
contained in this Agreement shall preclude i-STAT or Abbott from utilizing or
disclosing to others its Confidential Information or utilizing Confidential
Information received from the other Party as may be required
39
39
(a) for regulatory purposes, including Regulatory Filings required to obtain FDA
or other governmental approvals subject to requesting confidential treatment;
(b) for audit, tax or customs purposes subject to requesting confidential
treatment; (c) for purposes of preparing and filing patent applications
consistent with the terms of this Agreement; (d) by law or judicial order, with
the consent of the other Party, which consent shall not be unreasonably
withheld. With respect to Trade Secrets, the consent of the Disclosing Party (as
defined in Section 10.2) shall be required before any disclosure of such Trade
Secret, which consent shall not be withheld unreasonably.
10.4 Publication. Neither Party shall publish or make any presentation
regarding the R&D Program, results of the R&D Program, any Project Plan or any
Program Product, unless such publication has been reviewed and approved by the
other Party at least sixty (60) days prior to its submission for publication,
which approval shall not be withheld unreasonably. If requested, each party
shall allow the other Party a reasonable period of time to seek patent
protection before submitting such proposed disclosure for publication. Such
approval by the other Party shall not be required if such information has been
published previously, is in the public domain without breach of this Agreement,
or was approved or published in writing previously in substantially the same
format.
10.5 Public Announcements. Neither Party shall make any public
announcements concerning the Alliance Agreements, nor make any public statement
which includes the name of the other Party or any of its Affiliates, or
otherwise use the name of the other Party or any of its Affiliates in any public
statement or document, without the consent of the other Party, which consent
shall not be unreasonably withheld, except: (a) as may be required legally by
law or judicial order; or (b) either Party may include in a subsequent public
statement or document, information regarding the Alliance Agreements which has
already been approved by the other Party.
40
40
10.6 Confidential Treatment. i-STAT shall seek confidential treatment
for the terms and conditions of this Agreement to the fullest extent permitted
by the SEC and any other governmental agency or self-regulatory organization to
which i-STAT provides a copy of this Agreement or any of the other Alliance
Agreements. Prior to seeking confidential treatment from the SEC or any other
governmental agency or self-regulatory organization for any such document,
i-STAT shall consult with Abbott and ▇▇▇▇▇▇'▇ counsel and provide them with a
reasonable opportunity to request the inclusion of specified provisions in any
request by i-STAT for confidential treatment.
ARTICLE 11. NON-COMPETITION
*** CONFIDENTIAL TREATMENT REQUESTED.
41
41
ARTICLE 12. REPRESENTATIONS AND WARRANTIES
12.1 i-STAT Representations and Warranties as of the Signing Date and
Closing Date and thereafter:
12.1.1 Intellectual Property Representations and Warranties:
i-STAT agrees that it shall represent and warrant to Abbott in a writing which
shall be attached hereto as Schedule 12.1.1 as of the date that i-STAT
identifies specific i-STAT Know-How and Technology for incorporation into a
Project and lists such i-STAT Know-How and Technology in the Project Plan for
development of a particular Program Product, that:
(a) To the best of its knowledge, such i-STAT Know-How
and Technology has not been or will not be obtained
through any intentional activity, omission or
representation by i-STAT that would limit or destroy
the validity of or subrogate i-STAT's rights under
such i-STAT Know-How and Technology, and i-STAT has
no knowledge or information that would impact on or
affect the validity and/or enforceability of any
patents or potential patents included in i-STAT
Know-How and Technology;
(b) To the best of its knowledge, no actions are
threatened or pending before any court or
governmental agency or other tribunal relating to
such i-STAT Know-How and Technology other than (to be
supplied at time of warranty).
(c) To the best of its knowledge, no Third Party has
acquired, owns or possesses any right, title or
interest in or to, either directly or indirectly, the
Program Technology or Program Products which would
permit such Third Party to acquire, own or possess
such right, title or interest through i-STAT's
intellectual property rights in Program Technology
hereunder, and no Third Party possesses any rights
which
42
42
would permit such Third Party to Commercialize
Program Products due to any rights granted to it by
i-STAT; and
(d) i-STAT is in compliance and shall remain in
compliance with all material terms of any agreement
with a Third Party which grants rights to i-STAT for
technology under such i-STAT Know-How and Technology,
so as not to adversely affect any rights of Abbott
under this Agreement.
12.1.2 Special Representations and Warranties. (a) i-STAT
represents and warrants to Abbott as follows: The execution, delivery and
performance of this Agreement by i-STAT shall not be in conflict with or result
in the breach of any obligations of i-STAT under any agreement by and between
i-STAT and FUSO and i-STAT and HP, respectively, including without limitation,
the FUSO Agreement, the FUSO Development Agreement, the FUSO License Agreement,
the HP Stock Purchase Agreement, the HP Agreement or the HP License Agreement
and with regard to Program Products. This representation and warranty shall
survive for so long as the agreement between i-STAT and HP or FUSO,
respectively, pertaining to such representations and warranties is still in
effect.
12.2 Abbott Representations and Warranties Relating to Intellectual
Property. Abbott agrees that it shall warrant and represent to i-STAT in a
writing which shall be attached hereto as Schedule 12.2 as of the date that
Abbott identifies specific Abbott Know-How and Technology for incorporation into
a Project, and lists such Abbott Know-How and Technology in the Project Plan for
development of a particular Program Product that:
(a) To the best of its knowledge, such Abbott Know-How and
Technology has not been obtained or will not be obtained
through any intentional activity, omission or representation
by Abbott
43
43
that would limit or destroy the validity of or subrogate
▇▇▇▇▇▇'▇ rights under such Abbott Know-How and Technology, and
Abbott has no knowledge or information that would impact on or
affect the validity and/or enforceability of any patents or
potential patents included in Abbott Know-How and Technology;
(b) To the best of its knowledge, no actions are threatened or
pending before any court or governmental agency or other
tribunal relating to such Abbott Know-How and Technology other
than (to be supplied at time of warranty);
(c) To the best of its knowledge, no Third Party has acquired,
owns or possesses any right, title or interest in or to,
either directly or indirectly, the Program Technology or
Program Products which would permit such Third Party to
acquire, own or possess such right, title or interest through
▇▇▇▇▇▇'▇ intellectual property rights in Program Technology
hereunder, and no Third Party possesses any rights which would
permit such Third Party to Commercialize Program Products due
to any rights granted to it by Abbott; and
(d) Abbott is in compliance and shall remain in compliance with
all material terms of any agreement with a Third Party which
grants rights to Abbott for technology under such Abbott
Know-How and Technology, so as not to adversely affect any
rights of i-STAT under this Agreement.
12.3 General Representations and Warranties. Each Party represents and
warrants to the other Party as of the Signing Date and Closing Date that:
(a) It is a corporation duly organized and validly
existing under the laws of its state of
incorporation;
(b) It has the power and authority to execute and deliver
this Agreement and to perform its obligations
hereunder; and
44
44
(c) The execution, delivery and performance by it of this
Agreement and its compliance with the terms and
provisions hereof does not and will not conflict with
or result in a breach of any other agreement or
relationship.
ARTICLE 13. INDEMNIFICATION
13.1 Indemnifications by i-STAT.
13.1.1 General Indemnification.
i-STAT shall defend, indemnify and hold harmless Abbott and
its Affiliates and their officers, directors, employees and representatives,
from and against any suit, proceeding, claim, liability or loss including
attorneys' fees necessary to consider, advise and defend, ("Claims") which arise
out of or are attributable to any gross negligence or willful misconduct on the
part of i-STAT or its Affiliates and their employees, agents or representatives
which relates to i-STAT's and its Affiliates' performance hereunder.
Notwithstanding the above, i-STAT shall not be liable for Claims of any kind
which arise out of or are attributable to any gross negligence or willful
misconduct of Abbott or its Affiliates and their officers, directors, employees,
agents or representatives with regard to ▇▇▇▇▇▇'▇ performance hereunder.
13.1.2 Intellectual Property Indemnity. i-STAT agrees to and
shall defend, indemnify and hold harmless Abbott and its Affiliates and their
officers, directors, employees and representatives, from and against any Claim
and any damages awarded therefrom so far and to the extent as such suit or
proceeding is based upon an assertion that the i-STAT Know-How and Technology
used hereunder in Program Technology and/or Program Products constitutes an
infringement of any
45
45
patent, copyright, trademark or any other intellectual property right of a Third
Party; provided, that Abbott shall promptly notify i-STAT of such Claim, as set
forth in Section 13.3.
13.2 Indemnification by Abbott.
13.2.1 General Indemnification.
Abbott shall defend, indemnify and hold harmless i-STAT and its
Affiliates and their officers, directors, employees and representatives from and
against any Claims which arise out of or are attributable to any gross
negligence or willful misconduct on the part of Abbott or its Affiliates and
their officers, directors, employees, agents or representatives which relates to
▇▇▇▇▇▇'▇ and its Affiliates performance hereunder. Notwithstanding the above,
Abbott shall not be liable for Claims of any kind which arise out of or are
attributable to any gross negligence or willful misconduct of i-STAT, its
employees, agents or representatives with regard to i-STAT's and its Affiliates
performance hereunder.
13.2.2 Intellectual Property Indemnity. Abbott agrees to and
shall defend, indemnify and hold harmless i-STAT and its Affiliates and their
officers, directors, employees and representatives, from and against any Claim
and any damages awarded therefrom so far and to the extent as such suit or
proceeding is based upon an assertion that the Abbott Know-How and Technology
used hereunder in Program Technology and/or Program Products constitutes an
infringement of any patent, copyright, trademark or any other intellectual
property right of a Third Party; provided, that i-STAT shall promptly notify
Abbott of such Claim as set forth in Section 13.3.
13.3 Cooperation. Each Party shall promptly notify the other Party of
any Claim or potential Claim covered by the provisions of Section 6.4 and this
Article 13, and shall include sufficient information to enable the other Party
to assess the facts. If indemnification is sought as
46
46
a result of any Third Party or sublicensee claim or suit pursuant to Section
6.4, such notice to the indemnifying Party shall be given promptly by the Party
seeking such indemnification.
13.4 Insurance. i-STAT shall procure and maintain during the Term
comprehensive commercial liability insurance, including contractual and products
liability coverage, in the aggregate annual limits of $20,000,000. i-STAT shall
cause Abbott and its Affiliates to be named as an additional insured on such
policies, and i-STAT policies shall be primarily with respect to any
indemnification of Abbott and its Affiliates hereunder. i-STAT shall provide
Abbott with not less than thirty (30) days' prior written notice of any
cancellation, modification or reduction of coverage under such policies.
13.5 Liability Limitation. EXCEPT FOR THIRD PARTY OR SUBLICENSEE
LIABILITY ARISING UNDER ARTICLE 12, IN NO EVENT SHALL EITHER PARTY BE LIABLE FOR
INDIRECT, INCIDENTAL, PENAL OR CONSEQUENTIAL DAMAGES, OR OTHER SIMILAR DAMAGES
ARISING OUT OF THIS AGREEMENT.
ARTICLE 14. CONDITIONS TO CLOSING
The obligations of Abbott and i-STAT to execute the Alliance Agreements shall be
subject to the satisfaction of Abbott at the Signing Date and as of the Closing
Date of the following conditions:
(a) The representations and warranties of i-STAT contained herein
and in the other Alliance Agreements shall be true and correct
at and as of the Signing Date and at and as of the Closing
Date as though restated on and as of the Closing Date (except
in the case of any representation and warranty that by its
terms is made as of a date
47
47
specified therein, in which case such representation and
warranty shall be true and correct as of such date);
(b) The "Closing" as such term is defined in the Stock Purchase
Agreement shall have occurred or shall be occurring
simultaneously.
(c) Abbott shall have received from i-STAT a certificate signed by
an appropriate officer as to i-STAT's compliance with the
conditions set forth in paragraph (a) of this Section 14.
ARTICLE 15. MISCELLANEOUS
15.1 Force Majeure. Neither Party shall be held in breach of this
Agreement for failure to perform any of its obligations hereunder and the time
required for performance shall be extended for a period equal to the period of
such delay, provided that such delay has been caused by or is a result of any
acts of God; acts of the public enemy; civil strife; wars declared or
undeclared; embargoes; labor disputes, including strikes, lockouts, job actions
or boycotts; fires; explosions; floods; shortages of material or energy; events
caused by reason of laws or regulations or orders by any government,
governmental agency or instrumentality or by any other supervening unforeseeable
circumstances beyond the reasonable control of the Party so affected. The Party
so affected shall: (a) give prompt written notice to the other Party of the
nature and date of commencement of the force majeure event and its expected
duration; and (b) use its reasonable best efforts to relieve the effect of such
cause as rapidly as possible.
15.2 Notices. All notices hereunder shall be in writing and shall be:
(a) delivered personally; (b) mailed by registered or certified mail, postage
prepaid; or (c) sent by overnight courier; or (d) sent by facsimile or express
mail to the following addresses of the respective Parties:
If to i-STAT: i-STAT Corporation
48
48
President and Chief Executive Officer
▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇ ▇▇▇▇
▇▇▇▇▇▇▇▇▇, ▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇
Facsimile Number: (▇▇▇) ▇▇▇-▇▇▇▇
With copy to: Paul, Hastings, ▇▇▇▇▇▇▇▇ & ▇▇▇▇▇▇ LLP
▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇
▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Attention: ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇, Esq.
Facsimile Number: (▇▇▇) ▇▇▇-▇▇▇▇
If to Abbott: ▇▇▇▇▇▇ Laboratories
Director, Technology Licensing and Acquisitions
D9RK, AP6C
▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇ ▇▇▇▇
▇▇▇▇▇▇ ▇▇▇▇, ▇▇▇▇▇▇▇▇ ▇▇▇▇▇-▇▇▇▇
Facsimile Number: (▇▇▇) ▇▇▇-▇▇▇▇
With copy to: Divisional Vice President
Domestic Legal Division
D-322, AP6D
▇▇▇▇▇▇ Laboratories
▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇ ▇▇▇▇
▇▇▇▇▇▇ ▇▇▇▇, ▇▇▇▇▇▇▇▇ ▇▇▇▇▇-▇▇▇▇
Facsimile Number: ( ▇▇▇) ▇▇▇-▇▇▇▇
Notice shall be effective: (i) upon receipt if personally delivered, (ii) on the
third Business Day following the date of mailing if sent by registered or
certified mail; (iii) on the second Business Day following the date of delivery
to the express mail service if sent by express mail; and (iv) on the first
Business Day following the date of transmission or delivery to the overnight
courier if sent by facsimile or overnight courier. A Party may change its
address listed above by sending notice to the Party.
15.3 Assignment. Neither Party may assign its rights or obligations
under this Agreement without the prior written consent of the other Party, which
consent shall not be unreasonably withheld; provided, however, that Abbott may
assign this Agreement, in whole or in part, without
49
49
such consent, to an Affiliate of Abbott; and provided, further, that Abbott
shall promptly notify i- STAT of any such assignment. Any permitted assignee
shall assume all obligations of its assignors under this Agreement. No
assignment shall relieve any Party of responsibility for the performance of any
obligation which such Party may have or incur hereunder.
15.4 Binding Effect. This Agreement shall be binding upon and inure to
the benefit of each of the Parties and its successors and permitted assigns.
15.5 Dispute Resolution. Any controversy or claim arising out of or
relating to this Agreement, or the breach thereof, shall be resolved through the
alternate dispute resolution procedure ("ADR") described on Schedule 15.5;
provided, however, that this shall not prevent a Party from seeking or obtaining
injunctive relief relating to a breach of confidentiality under Article 10 in a
court of competent jurisdiction.
15.6 Relationship of the Parties. The relationship of the Parties under
this Agreement is that of independent contractors. Nothing contained in this
Agreement shall be construed so as to constitute the Parties as partners, joint
venturers, or agents of the other. Neither Party nor its Affiliates has any
express or implied right or authority under this Agreement to assume or create
any obligations or make any representations or warranties on behalf of or in the
name of the other Party or its Affiliates.
15.7 Non-Solicitation. The Abbott Diagnostics Division of Abbott
("ADD") and i-STAT each hereby agree that, during the Term and for a period of
*** thereafter, a Party shall not solicit to employ any professional level
employee of the other Party with whom it comes in contact during the performance
of this Agreement, so long as that employee is employed by that other Party,
without obtaining the prior written consent of the other Party; provided that:
(a) such employee has not been dismissed or otherwise terminated; and (b) such
employee has not answered a general solicitation for employment.
*** CONFIDENTIAL TREATMENT REQUESTED.
50
50
15.8 Headings. The captions to the Articles and Sections in this
Agreement are inserted for convenience only and are not a part hereof.
15.9 Waiver or Modification of Agreement. No waiver or modification of
any of the terms of this Agreement shall be valid unless in writing and signed
by authorized representatives of both Parties. Failure by either Party to
enforce any of its rights under this Agreement shall not be construed as a
waiver of such rights nor shall a waiver by either Party in one (1) or more
instances be construed as constituting a continuing waiver or as a waiver in
other instances.
15.10 Severability. If any term or provision of this Agreement for any
reason shall be held invalid, illegal or unenforceable in any respect, such
invalidity, illegality or unenforceability shall not affect any other term or
provision hereof, and this Agreement shall be interpreted and construed as if
such term or provision, to the extent the same shall have been held to be
invalid, illegal or unenforceable, had never been contained herein.
15.11 Entire Agreement. This Agreement including the Schedules, which
are incorporated herein by reference, together with the Alliance Agreements
including the StandStill Agreement and the Registration Rights Agreement, and
other documents exchanged in connection therewith sets forth the entire
understanding of the Parties concerning the subject matter hereof and supersedes
all written or oral prior agreements or understandings with respect thereto.
15.12 Governing Law. This Agreement and the legal relations between the
Parties hereunder shall be construed, interpreted and governed by the laws of
the State of New York, without regard to its choice of law principles.
51
51
15.13 Interpretation. When a reference is made to this Agreement to
Sections or Schedules, such reference shall be to a Section or Schedule to this
Agreement unless otherwise indicated. The words "include," "includes" and
"including" when used herein shall be deemed in each case to be followed by the
words "without limitation." The table of contents and headings contained in this
Agreement have been inserted for convenience of reference only and shall not be
relied upon in construing this Agreement. Use of any gender herein to refer to
any person shall be deemed to comprehend masculine, feminine, and neuter unless
the context clearly requires otherwise.
15.14 Counterparts. This Agreement may be executed in two (2) original
counterparts, each of which shall be deemed an original, but both of which
together shall constitute one and the same instrument.
15.15 Mutual Drafting. This Agreement is the joint product of Abbott
and i-STAT, and each provision hereof has been subject to the mutual
consultation, negotiation and agreement of the Parties and their respective
legal counsel and advisers and any rule of construction that a document shall be
interpreted or construed against the drafting party shall not be applicable.
[The remainder of this page intentionally left blank.]
52
52
[This page intentionally left blank.]
53
53
IN WITNESS WHEREOF, each Party has caused this Research and Development
and License Agreement to be executed by its duly authorized representative as of
the day and year last below written.
▇▇▇▇▇▇ LABORATORIES i-STAT CORPORATION
By: /s/ Miles ▇. ▇▇▇▇▇ By: /s/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
-------------------------- -----------------------------
Miles ▇. ▇▇▇▇▇ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
Executive Vice President President and Chief Executive Officer
Date: August 3, 1998 Date: August 3, 1998
54